承業生醫投資控股(股)有限公司
CHC HEALTHCARE GROUP

4164 TT

July, 2013

Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by CHC Health Care Group (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.

- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

- This Presentation includes certain statements that may be deemed “forward-looking statements”. All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

Executive Summary

Full Service Provider

- Full service solution provider for high-end Radiotherapy, Neurosurgery and Diagnostic Imaging Equipment
- Exclusive master distributor in Taiwan for premium brands

Dominant Market Share

- Dominant **55% share** of the Taiwan installed base of radiotherapy equipment, via sales of Elekta-branded equipment
- Market share has been **80-90%** for radiotherapy equipment since 2009

China Market Penetration

- China medical equipment distribution platform was set up in 2012
- Have hosted many Chinese health care professionals at our Taiwan HQ over the past 2 years, with CHC practices serving as a model for the use of advanced medical equipment in China.

Radiotherapy is our focus

7% of sales are derived from ophthalmology & dentistry-related equipment and supplements.

Radiotherapy sales, revenue sharing partnerships and value-added services in Taiwan accounted for **93%** of 2012 revenue.

The superior returns on these revenues have enabled CHC to maintain a **net margin in excess of 20%** in the past three years.

承業生醫 投資控股(股)有限公司
CHC HEALTHCARE GROUP

Value-Added Services with a Robust Distribution Channel

- CHC's equipment is used in **52 of the 68** local hospitals that have radiotherapy departments.
- Our market share for Brachytherapy equipment is **90%+.**



- Annual equipment maintenance & repair service fees are equivalent to **5-7%** of the total contract price, and profit margins are high.

- **12-15 year** radiotherapy equipment revenue-sharing agreements are increasing, and should prove to be a growing source of cash flow for years to come.

承業生醫投資控股(股)有限公司 CHC HEALTHCARE GROUP

CHC Provides a Full Spectrum of Services



We work with world-renowned brands…

Radiotherapy and Neurology

ELEKTA

Nucletron
AN ELEKTA COMPANY

PTW FREIBURG

C-RAD

ELEKTA
NEUROSCIENCE

Leica
MICROSYSTEMS

ISP

sono wand®

iba

Ophthalmology and Dentistry

YOSHIDA

Kodak Dental Systems
by Carestream Dental

Ritter®
[DENTAL TECHNOLOGY]

Leica
MICROSYSTEMS

HEINE

Heraeus

LUMENIS.
Enhancing Life. Advancing Technology.

TECHNOLAS™
PERFECT VISION

And Aggressively Introducing New Products

Diagnostic X-Ray (DR X-Ray)

Swissray

Proton therapy

iba

Value-added Services

CHC's experienced consulting and service team is a critical factor in our success.

Manufacturers rely on CHC to provide this operational support and after-sales service.

CHC's 30 years of investment in establishing, training and re-certifying its 60+ member team is a key differentiating factor from its competitors.

CHC's Competitive Advantage in China



- Complete Product Line
- Successful Taiwan Experience
- Full Service Solution Capability
- Clinical Education and Training
- Flexible Sales Model
- Cross-strait Medical Conferences

Radiotherapy Equipment Market in China

- There are about 1,300 Class Ⅲ hospitals in China. 7 of the Top 10 clinics use Elekta.
- China is the third largest medical device market in the world and domestic manufacturers' products do not yet possess world class technology.
- Elekta China, is the No.1 player in oncology (44% market share). CHC is well-positioned to help Elekta maintain its No. 1 rank.
- As the PRC gov't strives to deliver improved health care, total annual health care expenditures are projected to grow by a CAGR of 21% between 2006 ($120 bn) and 2015 ($700 bn).



Hospital structure in China



Radiotherapy market share in China

承業生醫投資控股(股)有限公司 CHC HEALTHCARE GROUP

High Demand for Radiotherapy Services







Diagnostic Imaging Products Account for Over 25% of the Global Medical Device Market

Global Medical Device market breakdown



Global Diagnostic Imaging Market breakdown



Units of CR, MRI, NM in Taiwan (Unit: Sets)



Usage of CR, MRI, NM in Taiwan (Unit: Times)



	2005	2006	2007	2008	2009	2010
CT	981,805	1,029,200	1,141,864	1,268,921	1,391,606	1,466,001
MRI	316,922	341,681	383,505	426,688	483,008	522,885
NM	291,410	318,004	396,750	500,674	423,601	443,314

Source: Department of Health

Proton Pencil Beam Scanning



Protons and Charged Particles





Protons give Conformal Dose and Low Integral Dose

Proton Design Flexibility

*Proteus***PLUS** TM
UNIVERSAL PROTON THERAPY SOLUTION
Active and Passive treatment modes

*Proteus***ONE** TM
COMPACT PROTON THERAPY SOLUTION
Active treatment only



1800 m²

Profitable PT center
for **1/6** the size



300 m²

承業生醫 投資控股(股)有限公司
CHC HEALTHCARE GROUP

Our Vision

Product Line Expansion

Product Pipeline

Existing Products

IBA Proton Therapy

Philips Radiological Imaging Equipment

Swissray Radiological Imaging Equipment (Exclusive Greater China Distributor

White Essence Dental Clinic (Exclusive Greater China Distributor)

Ophthalmology & Dentistry Equipment

Yoshida Dental Equipment (Exclusive Greater China Distributor)

Neuroscience Equipment

Elekta/Linear Accelerator

Elekta Linear Accelerator in 5 Southern China Provinces

台灣

地區的拓展

承業生醫 投資控股(股)有限公司 CHC HEALTHCARE GROUP

We Aim to Become the Leading Medical Equipment Full Service Solutions Provider in the Asia-Pacific Region

iba	Belgium	ELEKTA	Sweden	TECHNOLAS PERFECT VISION	Germany	Swissray	Swiss
BAUSCH + LOMB 博士倫	USA	YOSHIDA	Japan	HEINE	Germany	Leica MICROSYSTEMS	Swiss
Carestream	USA	Nucletron AN ELEKTA COMPANY	Nederland	Heraeus	Germany	LUMENIS Enhancing Life. Advancing Technology.	Israel
ISP	USA	PTW	Germany				

Financial Highlights









承業生醫 投資控股(股)有限公司
CHC HEALTHCARE GROUP

2013 Q1 Highlights

NT$,000	2013Q1	2012Q1	Change
Revenue	368,644	343,201	7.4%
Gross profit	67,312	98,005	-31.3%
Operating profit	8,340	42,960	-80.6%
Net profit	4,090	39,246	-89.6%
Net profit attribute to shareholders	4,847	38,946	-87.6%
EPS	0.04	0.36	-88.9%

Key ratios

%	2013Q1	2012Q1	Change
Gross margin	18	29	-11 ppt
Operating margin	2	13	-11 ppt
Net margin	1	12	-11 ppt

Peer Comparison Charts









Source: Company data,Capital IQ

承業生醫 投資控股(股)有限公司
CHC HEALTHCARE GROUP

Thank you

承業生醫 投資控股(股)有限公司
CHC HEALTHCARE GROUP